These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 21323610)

  • 1. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies.
    Barochia A; Solomon S; Cui X; Natanson C; Eichacker PQ
    Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):479-94. PubMed ID: 21323610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo Toll-like receptor 4 antagonism restores cardiac function during endotoxemia.
    Ehrentraut S; Lohner R; Schwederski M; Ehrentraut H; Boehm O; Noga S; Langhoff P; Baumgarten G; Meyer R; Knuefermann P
    Shock; 2011 Dec; 36(6):613-20. PubMed ID: 22089127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
    Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
    Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis.
    Kalil AC; LaRosa SP; Gogate J; Lynn M; Opal SM;
    Shock; 2011 Oct; 36(4):327-31. PubMed ID: 21701421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
    Opal SM; Laterre PF; Francois B; LaRosa SP; Angus DC; Mira JP; Wittebole X; Dugernier T; Perrotin D; Tidswell M; Jauregui L; Krell K; Pachl J; Takahashi T; Peckelsen C; Cordasco E; Chang CS; Oeyen S; Aikawa N; Maruyama T; Schein R; Kalil AC; Van Nuffelen M; Lynn M; Rossignol DP; Gogate J; Roberts MB; Wheeler JL; Vincent JL;
    JAMA; 2013 Mar; 309(11):1154-62. PubMed ID: 23512062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564).
    Sun Y; Pearlman E
    Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1247-54. PubMed ID: 18936141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis.
    Tidswell M; LaRosa SP
    Expert Rev Anti Infect Ther; 2011 May; 9(5):507-20. PubMed ID: 21609262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eritoran attenuates tissue damage and inflammation in hemorrhagic shock/trauma.
    Korff S; Loughran P; Cai C; Lee YS; Scott M; Billiar TR
    J Surg Res; 2013 Oct; 184(2):e17-25. PubMed ID: 23777984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting myeloid differentiation 2 for treatment of sepsis.
    Duan G; Zhu J; Xu J; Liu Y
    Front Biosci (Landmark Ed); 2014 Jun; 19(6):904-15. PubMed ID: 24896325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits.
    Wasan KM; Risovic V; Sivak O; Lee SD; Mason DX; Chiklis GR; McShane J; Lynn M; Wong N; Rossignol DP
    Pharm Res; 2008 Jan; 25(1):176-82. PubMed ID: 17849177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of eritoran tetrasodium, a toll-like receptor 4 antagonist, on intestinal microcirculation in endotoxemic rats.
    Yeh YC; Ko WJ; Chan KC; Fan SZ; Tsai JC; Cheng YJ; Sun WZ
    Shock; 2012 May; 37(5):556-61. PubMed ID: 22392144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease in the inflammatory cytokines of LPS-stimulated PBMCs of patients with atherosclerosis by a TLR-4 antagonist in the co-culture with HUVECs.
    Talepoor AG; Rastegari B; Kalani M; Doroudchi M
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108295. PubMed ID: 34735917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trial watch: Sepsis study failure highlights need for trial design rethink.
    Tse MT
    Nat Rev Drug Discov; 2013 May; 12(5):334. PubMed ID: 23629495
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of the Toll-like receptor 4 antagonist eritoran on retinochoroidal inflammatory damage in a rat model of endotoxin-induced inflammation.
    Ekici F; Karaca EE; Korkmaz S; Yüksel O; Gülbahar Ö; Alper M; Ercan S; Or M
    Mediators Inflamm; 2014; 2014():643525. PubMed ID: 25165412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling.
    Mcdonald KA; Huang H; Tohme S; Loughran P; Ferrero K; Billiar T; Tsung A
    Mol Med; 2015 Mar; 20(1):639-48. PubMed ID: 25375408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.
    Rossignol DP; Wong N; Noveck R; Lynn M
    Innate Immun; 2008 Dec; 14(6):383-94. PubMed ID: 19039062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury.
    Shimamoto A; Chong AJ; Yada M; Shomura S; Takayama H; Fleisig AJ; Agnew ML; Hampton CR; Rothnie CL; Spring DJ; Pohlman TH; Shimpo H; Verrier ED
    Circulation; 2006 Jul; 114(1 Suppl):I270-4. PubMed ID: 16820585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The TLR4 antagonist Eritoran protects mice from lethal influenza infection.
    Shirey KA; Lai W; Scott AJ; Lipsky M; Mistry P; Pletneva LM; Karp CL; McAlees J; Gioannini TL; Weiss J; Chen WH; Ernst RK; Rossignol DP; Gusovsky F; Blanco JC; Vogel SN
    Nature; 2013 May; 497(7450):498-502. PubMed ID: 23636320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deactivation of the lipopolysaccharide antagonist eritoran (E5564) by high-density lipoprotein-associated apolipoproteins.
    Fleischer JG; Rossignol D; Francis GA; Chan T; Lynn M; Wasan KM
    Innate Immun; 2012 Feb; 18(1):171-8. PubMed ID: 21382909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eritoran Suppresses Colon Cancer by Altering a Functional Balance in Toll-like Receptors That Bind Lipopolysaccharide.
    Kuo WT; Lee TC; Yu LC
    Cancer Res; 2016 Aug; 76(16):4684-95. PubMed ID: 27328732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.